Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Cantharis
- Development stage
- Unknown
- Lead developer
- Guizhou Yibai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Compound Cantharis is a Traditional Chinese Medicine (TCM) formulation primarily developed and marketed by Guizhou Yibai Pharmaceutical. It is typically administered as an oral capsule and is composed of several ingredients, including Cantharis (Spanish fly), Ginseng, Astragalus, and other herbal components. The primary active constituent derived from Cantharis is cantharidin. The drug is indicated for the treatment of various malignancies, such as primary liver cancer, lung cancer, and gastric cancer, often serving as an adjuvant therapy to chemotherapy or radiotherapy. Its therapeutic effects are attributed to the induction of apoptosis in tumor cells, inhibition of tumor growth, and enhancement of the patient's immune response.
- Brand names
- Compound Cantharis Capsules
- Other names
- Fufang Banmao JiaonangCompound Cantharidin Capsules
02
Targets
PP1 (Protein phosphatase 1)PP2A-C (Protein phosphatase 2A catalytic subunit)PPP5C (Serine/threonine-protein phosphatase 5)CN (Calcineurin)
Beyond the preview
Go deeper on Compound Cantharis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound Cantharis.